Ornipressin (omithine-8-vasopressin, POR-8) is the most commonly used vasopressin analogue in Germany, Switzerland, New Zealand and Australia. While it has minimal antidiuretic activity whilst maintaining equipotent vasoconstrictor activity as the natural hormone, vasoprssin.
CAT No: 10-101-40
CAS No:3397-23-7
Synonyms/Alias:ORNIPRESSIN;Ornipressine;Ornipresina;Orpressin;3397-23-7;POR 8;Ornipressin [INN];Ornipressina;Ornipressinum;Ornithine Vasopressin;8-Ornithinevasopressin;8-L-Ornithinevasopressin;Orn(8)-vasopressin;POR 8 Sandoz;(Orn8) Vasopressin;POR-8;Ornipressina [DCIT];Ornipresina [INN-Spanish];Ornipressine [INN-French];Ornipressinum [INN-Latin];UNII-1KTH6N080W;Vasopressin, 8-L-ornithine-;1KTH6N080W;ORNIPRESSIN [MI];EINECS 222-253-8;ORNIPRESSIN [MART.];ORNIPRESSIN [WHO-DD];(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;CHEMBL1819440;Ornipressin (INN);Ornipressin Diacetate Salt;Ornipresina (INN-Spanish);Ornipressine (INN-French);Ornipressinum (INN-Latin);ORNIPRESSIN (MART.);(2S)-N-[(2S)-5-Amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13R,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;CYS-TYR-PHE-GLN-ASN-CYS-PRO-ORN-GLY-NH2 (1-6 DISULFIDE);CYS-TYR-PHE-GLN-ASN-CYS-PRO-ORN-GLY-NH2 (1-6 DISULPHIDE);POR 8 Sandoz (TN);(2S)-N-((2S)-5-amino-1-((2-amino-2-oxoethyl)amino)-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-((4-hydroxyphenyl)methyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide;Vasopressin, Ornithine;Ornithine 8 Vasopressin;Ornithine-8-Vasopressin;SCHEMBL296322;H01BA05;CHEBI:136020;MUNMIGOEDGHVLE-LGYYRGKSSA-N;HY-P0083;BDBM50350865;AKOS030529555;CS-5839;DB13464;NCGC00509864-02;DA-56485;NS00049980;Q3038432;(S)-N-((S)-5-amino-1-((2-amino-2-oxoethyl)amino)-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide;222-253-8;
Ornipressin is a synthetic peptide analog of vasopressin, characterized by its potent vasoconstrictive properties and selective affinity for vascular V1 receptors. As a nonapeptide, it is structurally modified to enhance stability and receptor specificity, making it a valuable tool in physiological and pharmacological research. Its ability to modulate vascular tone and impact smooth muscle contraction has established ornipressin as a key agent for investigating hemodynamic regulation and peptide-receptor interactions. The compound's distinct profile supports its use in diverse experimental settings, particularly those focused on vascular biology, peptide signaling, and the development of novel vasoactive agents.
Vascular physiology research: Ornipressin's primary utility lies in its capacity to induce vasoconstriction through selective activation of V1 receptors on vascular smooth muscle cells. Researchers employ it to model and dissect the mechanisms of blood vessel contraction, allowing for precise studies of arterial tone regulation and systemic vascular resistance. Its predictable pharmacodynamics enable controlled experimentation in both in vitro and in vivo systems, facilitating the elucidation of signaling pathways involved in vascular homeostasis and the identification of factors influencing vascular reactivity.
Peptide-receptor interaction studies: As a well-characterized vasopressin analog, ornipressin serves as a reference ligand for exploring peptide-receptor binding dynamics and downstream signaling events. Its selective receptor profile is particularly advantageous in experiments designed to differentiate the effects of V1 versus V2 receptor activation, supporting the mapping of receptor subtype distributions and the development of receptor-specific probes. This makes it an essential reagent for advancing the understanding of peptide hormone action and receptor-mediated cellular responses.
Signal transduction analysis: The compound's ability to trigger intracellular cascades, such as phospholipase C activation and calcium mobilization, renders it a valuable tool in the investigation of signal transduction mechanisms. By providing a controlled stimulus, ornipressin enables researchers to probe the molecular events underlying G protein-coupled receptor (GPCR) signaling in vascular and non-vascular tissues. These studies contribute to a broader comprehension of how peptide hormones orchestrate complex physiological processes at the cellular level.
Pharmacological profiling: Ornipressin is frequently utilized in the characterization of novel pharmacological agents targeting the vasopressin receptor family. Its defined activity profile allows for the benchmarking of receptor agonists, antagonists, and modulators, supporting drug discovery efforts and the validation of candidate compounds. Comparative studies involving this peptide analog help delineate structure-activity relationships and optimize the selectivity and efficacy of new vasoactive molecules.
Experimental model development: The reproducible vasoconstrictive effects of ornipressin have made it a standard agent for establishing experimental models of altered vascular tone in laboratory animals and isolated tissue preparations. Such models are instrumental in evaluating the physiological consequences of acute or chronic changes in vascular resistance, assessing the impact of genetic modifications, and testing the efficacy of potential therapeutic interventions targeting the vasopressinergic system. The compound's stability and well-characterized action profile ensure reliability and consistency across experimental protocols.
We sought to evaluate the efficacy and side effect profile of a small dose of ornipressin, a vasopressin agonist specific for the V1 receptor, administered to reverse the hypotension associated with combined general/epidural anesthesia. A total of 60 patients undergoing intestinal surgery were studied. After the induction of anesthesia, 7-8 mL of bupivacaine 0.5% with 2 microg/kg clonidine and 0.05 microg/kg sufentanil after an infusion of 5 mL of bupivacaine 0.06% with 0.5 microg x kg(-1) x h(-1) clonidine and 0.1 microg/h of sufentanil were administered by an epidural catheter placed at T7-8 vertebral interspace. When 20% reduction of baseline arterial blood pressure developed, patients were randomly assigned to receive, in a double-blinded design, dopamine started at 2 microg x kg(-1) x min(-1), norepinephrine started at 0.04 microg x kg(-1) x min(-1), or ornipressin started at 1 IU/h. Fifteen patients presenting without hypotension were used as control subjects. Beside routine monitoring, S-T segment analysis, arterial lactacidemia, and gastric tonometry were performed. Ornipressin restored arterial blood pressure after 8 +/- 2 vs 7 +/- 3 min in the norepinephrine group and 11 +/- 3 min in the dopamine group (P < 0.05). This effect was achieved with 2 IU/h of ornipressin in most of the patients (11 of 15). Ornipressin did not induce any modification of the S-T segment; however, it significantly increased intracellular gastric PCO(2) (P < 0.05), indicating splanchnic vasoconstriction.
De Kock, M., Laterre, P. F., Andruetto, P., Vanderessen, L., Dekrom, S., Vanderick, B., & Lavand'homme, P. (2000). Ornipressin (Por 8): an efficient alternative to counteract hypotension during combined general/epidural anesthesia. Anesthesia & Analgesia, 90(6), 1301-1307.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More